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ABSTRACT 34 
Objective: Sex hormone-binding globulin (SHBG) binds and transports testosterone and estradiol in 
plasma. The possibility that SHBG is a mixture of transporting proteins has been postulated. We analyzed 36 
in parallel the effects of obesity status on the levels and binding capacity of circulating SHBG and their 
relationship with testosterone and estradiol.  38 
Design: Anthropometric measures and plasma were obtained from apparently healthy young (i.e. 35 ± 7 
years) premenopausal women (n=32) and men (n=30), with normal weight and obesity (BMI>30 kgm-2). 40 
Methods: SHBG protein (Western blot), as well as the plasma levels of testosterone, estradiol, cortisol 
and insulin (ELISA) were measured. Specific binding of estradiol and testosterone to plasma SHBG was 42 
analyzed using tritium-labelled hormones.  
Results: Significant differences in SHBG were observed within the obesity status and gender, with 44 
discordant patterns of change in testosterone and estradiol. In men, testosterone occupied most of the 
binding sites. Estrogen binding was much lower in all subjects. Lower SHBG of morbidly obese (BMI>40 46 
kgm-2) subjects affected testosterone but not estradiol. The ratio of binding sites to SHBG protein levels, 
was constant for testosterone, but not for estradiol. The impact of gender was maximal in morbid obesity, 48 
with men showing the highest binding / SHBG ratios. 
Conclusions: The results reported here are compatible with SHBG being a mixture of at least two 50 
functionally different hormone-binding globulins, being affected by obesity and gender, and showing 
different structure, affinities for testosterone and estradiol, and also different immunoreactivity.  52 
 
  54 
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INTRODUCTION 
Hormone-binding globulins are serpins, whose main role is to specifically bind and transport 56 
steroid and thyroid hormones in plasma. Sex hormone-binding globulin (SHBG) essentially binds / 
transports testosterone and estradiol 1. The finding of its possible use as marker of a number of metabolic 58 
2, 3 or psychological 4 disorders has contributed to enhance the study of SHBG role in the control of gene 
expression 5 and sex hormone levels 6, 7, as well as its more than probable implication in metabolic 60 
syndrome (MS) 8. 
The function of SHBG is far from being fully understood. In fact, although it binds the hormone 62 
ligands in a high-affinity specific way, SHBG levels in plasma are low in comparison with albumin and 
other plasma proteins. The latter bind non-specifically these same hormones with high capacity and low 64 
affinity. The equilibrium of free hormone levels, thus, is not solely dependent on SHBG binding ability or 
levels, but also on its interaction with tissues and their complex and variably modulated compartmentation 66 
9. The absence of SHBG in rodents, in contrast with CBG, present in them and in humans, may hint at 
additional functions for this serpin, but the presence of a specific testosterone-binding protein in rodent 68 
testicles 10, with a marked structural and gene parallelism with SHBG 11, 12 suggests that at least for this 
organ, a specific protein binding testosterone is required.  70 
The high-affinity binding of sex hormones to SHBG competes with cell receptors, altering its 
direct availability, which prompts the question whether SHBG main role is to transport the hormones, or 72 
retain them to modulate their binding to cell membranes, including the specific binding of SHBG itself 13. 
This sequestering role has been postulated for tissues, where membrane-related hormone-binding 74 
globulins may act barrier-like to limit or control the access of active hormones to cells, as is the case for 
CBG 14. However, hormone-binding globulins are required as vector for transfer of hormones to cell 76 
ligands 15, to elicit effects on gene expression and the activation of other cell functions 16, 17. 
SHBG is a glycoprotein 18, which appears in plasma as a dimer, containing two subunits, each 78 
one having a site able to bind testosterone, dihydrotestosterone or estradiol 19. The affinity for 
testosterone has been found to be higher than for estradiol 20 in line with the function of the precursor 80 
testosterone-binding protein of rodents compared with that of plasma and testicles in rabbits 21. In human 
plasma, SHBG has been found in several forms of variable molecular weight, distributed in markedly 82 
different proportions 22, 23; however, they shared the peptide size and immuno-reacting properties, albeit 
only partially 22, 24. The difference in size has been largely attributed to the varying proportion of 84 
oligosaccharide chains 23, 25. SHBG hormone-binding affinity can be changed by molecular modulation of 
the serpin structure, such as localized proteolysis 26, proteolytic cleavage resulting in increased free 86 
hormone levels because of loss of affinity of the protein to its ligand 2. Other possible modifications of 
SHBG structure / binding are the formation of O- or N-glycans 27, 28. An important factor of variability / 88 
regulation is the complex control 29, 30 of the expression of the single SHBG gene described 12, able to 
generate different products 12. In addition, a number of genetic variants, showing different hormone-90 
binding affinities, has been described 31, 32. 
Plasma concentrations of free testosterone and estradiol are related to the levels of SHBG 33. Sex 92 
affects markedly the levels 34, 35 and function of SHBG, essentially altering the levels of testosterone 36. 
The important modulatory effects of estradiol and testosterone, confronting (or allied to) the effects of 94 
glucocorticoids 37 and insulin 38, 39 have been clearly established to show sex-related differences 40, 41 
especially under conditions of predominance of insulin resistance and glucocorticoid action as in 96 
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metabolic syndrome (MS) 37, 41. SHBG has been associated to the risk of MS in men 38, 42, independently 
of testosterone levels 43, whereas the relation of this syndrome with total or free testosterone is –at 98 
most— weak 44, 45. Women with MS showed increased testosterone and lower SHBG independently of 
menopausal status 46. 100 
Obesity is known to lead to insulin resistance 47, increase the risk of MS 48, and it is also 
associated with hypercortisolism 49, hypoandrogenism 42 and increased estrogens 50. In the present study 102 
we studied whether SHBG function is modified by obesity status. The key question was to determine 
whether the changes that SHBG experiences with obesity are a direct consequence of the existence of 104 
different molecular species of this protein. 
 106 
SUBJECTS AND METHODS 
Study population 108 
A sample of 62 subjects (32 of them women) of Caucasian origin, aged between 18 and 50 y (i.e. 
35 ± 7 y) and including patients at the extremes of the weight continuum [16 participants with severe 110 
obesity (BMI≥40 kg.m-2), 19 obese subjects, and 28 age and gender-matched healthy-weight controls 
(BMI<25 kgm-2)], was enrolled for hormonal and circulating assessment of target proteins. Six groups of 112 
subjects were established and studied comparatively: 1) women with normal weight: BMI<25 kgm-2;, 2) 
obese women: 30≤BMI<40 kgm-2; 3) morbid obese women: BMI>40 kgm-2; 4) men with normal weight: 114 
BMI<25 kgm-2;, 5) obese men: 30≤BMI<40 kgm-2; 3) morbid obese men: BMI>40 kgm-2. Inclusion 
criteria, in addition to the BMI ranges described above, were the absence of any systemic disease, and 116 
the absence of any infections in the previous month. None of the subjects was taking medication 
(including glucocorticoids or estrogens) or showed evidence of metabolic disease other than obesity. All 118 
subjects reported that their body weight had been stable for at least 3 months before the study. Liver 
disease and thyroid dysfunction were specifically excluded by biochemical workup. All women had regular 120 
menstrual cycles and were studied on days 3–8 of the cycle. All participants were in apparently good 
health, and free of cardiovascular pathologies, clinically defined diabetes or hypertension. 122 
The protocol was approved by the Hospital Ethics Committee, and informed consent was 
obtained from each subject.  124 
Baseline studies included a standardized questionnaire, physical examination and common 
laboratory tests. Height and weight were measured with the participant in light clothing and barefoot. BMI 126 
was calculated, and blood pressure was measured in the supine position, using a sphygmomanometer of 
appropriate cuff size; the first and fifth phases were recorded.  128 
 
Analytical procedures 130 
Blood samples were collected, after a 12-hour fast, into blood collection tubes with a serum 
separator. After 15 minutes, tubes were centrifuged at 1500xg for 10 min at room temperature. The 132 
serum glucose was measured in duplicate by a glucose oxidase/ peroxidase method (Glucose Analyzer 
2; Beckman Coulter, Inc., Brea, CA USA). The coefficient of variation was 1.9%. Serum insulin levels 134 
were measured in duplicate by monoclonal immunoradiometric assay (Medgenix Diagnostics, Fleunes, 
Belgium). The lowest limit of detection was 28 pM. The intraassay coefficient of variation was 5.2% at a 136 
concentration 70 pM and 3.4% at a 900 pM. The interassay coefficients of variation were 6.9% and 4.5% 
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at 100 pM and 620 pM, respectively. Blood glycosylated hemoglobin (HbA1c) proportions were analyzed 138 
by high pressure liquid chromatography (Merck Diagnostics, Darmstadt, Germany), with coefficients of 
variation below 4%. The range for HbA1c in glucose-tolerant subjects was 3.8 – 5.4%. Total serum 140 
cholesterol was measured through the reaction of cholesterol esterase/oxidase/ peroxidase, using a 
BM/Hitachi 747 analyzer (Hitachi, Tokyo, Japan). HDL cholesterol was quantified after precipitation with 142 
polyethylene glycol at room temperature. Total serum triacylglycerols were measured through lipolysis 
and the analysis of glycerol evolved with glycerol-phosphate-oxidase/ peroxidase. Whole blood 144 
hemoglobin levels (containing EDTA) were determined by a routine laboratory method (Coulter 
Electronics, Hialeah, FL USA).  146 
Solid-phase enzyme-linked immunosorbent assays (ELISA) based on the sandwich principle 
were used for the quantitative determination of plasma estradiol (kit EIA-2693) and testosterone (kit EIA-148 
1559, both from DRG International; Marburg, Germany). Plasma cortisol was determined by microparticle 
enzyme immunoassay (IMX system, Abbott Laboratories, North Chicago, IL USA), with intra and 150 
interassay coefficients of variation less than 8% 51.  
 152 
Western blot of SHBG 
Plasma SHBG was estimated by Western blot using monoclonal anti-human SHBG (LS-154 
C198189; LifeSpan Biosciences, Seattle, WA USA) as primary antibody, and polyclonal against albumin 
(sc-46293, Santa Cruz Biotechnology, Santa Cruz, CA USA) all of them raised against representative 156 
peptides. Proteins were run by SDS-PAGE (100 gL-1  resolving gel; 40 gL-1 stacking gel). A protein MW 
marker scale (kaleidoscope, BioRad, Berkeley, CA USA) was included in one of the wells. Samples of 1-2 158 
µL of plasma were used. Proteins were transferred to PVDFImmobilon (Millipore, Billerica, MA USA) 
membranes, which were visualized with Ponceau red. The membranes were blocked with TBST and 50 160 
gL-1 powdered skimmed milk; then they were incubated at 4 ºC overnight with the primary antibody 
diluted 1/2000. The membranes were, then, washed four times and then exposed (for 1 h at room 162 
temperature), diluted 1/3000, to the secondary antibody. After four washings, chemiluminiscence was 
analyzed using ECL (Millipore) for 5 min. Then, densitometric measurements were done using the Total-164 
Lab program (Nonlinear USA, Durham, NC USA). This Western blot is an adaptation of that previously 
developed by our group for the measurement of rat plasma CBG 52. 166 
 
Hormone-binding assays 168 
The basic procedure for hormone-binding assays was the same described by us previously for 
CBG 52. In short: samples of just-thawed plasma (10 µL) were mixed with 1 mL of PBS (phosphate buffer-170 
saline) pH7.4 containing 1 g/L gelatin. Total binding was estimated using 0.150 mL of diluted supernatant, 
0.025 mL of PBS-gelatin, and 0.025 mL of 3H-labelled estradiol (NET317: (2,4,6,7-3H)-17β-estradiol, 172 
Perkin-Elmer, Boston MA USA; specific activity 2.8 GBqmmol-1) or testosterone  (NET370:  (1,2,6,7 3H)-
testosterone, Perkin-Elmer, specific activity 2.6 GBqmmol-1). Hormones' final concentration was 30 nM, 174 
with a specific radioactivity of 12 kBqnmol-1). Non-specific binding was estimated under the same 
conditions, but now adding 0.025 mL of non-labelled hormone in PBS-gelatin (final concentration 15 µM). 176 
In both cases, the tubes were incubated under gentle shaking for 20 min at 37 ºC followed by 2 h at 4 ºC. 
Then 0.200 mL of chilled dextran-charcoal PBS-gelatin buffer were added, and the tubes were vortexed 178 
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and kept 10 min in ice. Finally, the tubes were centrifuged 10 min at 4 ºC and 2,000xg. Aliquots of the 
supernatants were used to measure the radioactivity bound to protein through liquid scintillation counting. 180 
 
Statistical methods 182 
Statistical comparisons were done using two-way ANOVA analyses (sex, obesity), with the 
Statgraphics Centurion XVI program package (Statpoint Technologies, Warrengton VA USA). 184 
Correlations were determined using the Prism 5 package (Graph-Pad Software Inc, La Jolla, CA USA). 
Before statistical analysis, normal distribution and homogeneity of the variables were tested. Levels of 186 
statistical significance were set at P <0.050. 
 188 
RESULTS 
Table 1 shows the basic plasma anthropometric and metabolic values of the six experimental 190 
groups. As expected, increased weight was concomitant with higher triacylglycerol levels in men and 
women, as well as with increased glycaemia, insulin and HOMA-IR.  192 
Table 2 presents the levels of plasma hormones and ratios between these levels. Estradiol 
concentrations showed no significant differences between women (in the follicular phase) and men. 194 
Morbid obesity was associated with increased estradiol levels, especially in men. As expected, 
testosterone showed marked sex-related differences, increasing with the severity of obesity in women 196 
and decreasing in men. No significant differences were observed regarding basal cortisol 
The ratio of testosterone to estradiol concentrations showed significant differences according to 198 
sex and obesity. Cortisol/ testosterone ratios were significantly different in obese women, but not in obese 
men. In contrast, the cortisol/ estradiol ratio was significantly different in obese men. The estradiol/ insulin 200 
ratios were similar according to sex and obesity status; however, the testosterone/ insulin ratios were 
clearly different for sex and BMI, being the effects of obesity a consequence of the 6-fold difference 202 
between morbidly obese men and controls. 
Plasma SHBG binding capacity for estradiol and testosterone is depicted in Figure 1. Estradiol 204 
binding showed no significant effect of sex, but obesity severity resulted in significant differences, solely 
attributable to males, since the morbid obese had much higher and significantly different binding values 206 
than those obese or with normal weight. The pattern for testosterone binding was quite different, with 
significant effects of both sex and obesity, the latter attributable, again to the group of men, with morbidly 208 
obese subjects showing the lowest testosterone binding values. These differences were magnified in the 
estradiol vs. testosterone binding ratio. Both sex and obesity showed significant differences, with rather 210 
uniform ratios for all groups except for the morbid obese men, with ratios several-fold higher than in all 
other groups. 212 
Figure 2 shows the levels of testosterone and estradiol as a proportion of SHBG binding capacity. 
The only significant differences observed were for sex in the case of testosterone, since in men the levels 214 
accounted for 60-80% of maximal binding capacity of SHBG against 5-20% for women. These data 
contrast with the rather uniform 1-3 % values for estradiol levels vs. binding. 216 
Figure 3 presents the amount of SHBG protein in plasma, determined through Western blot, 
Normal-weight women had almost 2.5-fold higher levels of circulating SHBG than the corresponding 218 
group of men; these differences were observed again in the morbid obese groups, but with all values 
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practically halved. These differences were statistically significant according to sex (lower values in men) 220 
and obesity status (decreasing values with increasing obesity). 
When estradiol or testosterone binding were related to the amount of SHBG protein (Figure 4), 222 
the resulting binding / Western blot ratios showed the actual capacity to bind the hormones with respect 
to the amount of protein present in plasma (i.e. the total binding capacity being a correlate of the amount 224 
of functional protein present). This value is ancillary to the number (or affinity) of the binding sites per 
molecule of protein. Estradiol binding was markedly different among morbidly obese men. Thus, the 226 
ability to bind was a uniform correlate of the amount of SHBG available, but in morbid obese men the 
ability to bind estradiol was much higher than that corresponding to the protein detected. In the case of 228 
testosterone, however, no significant differences for sex or obesity were found, with closely similar ratios 
of binding/ SHBG protein ratios for all groups. 230 
 
DISCUSSION 232 
SHBG binds both testosterone and estradiol, but not with the same affinity 1, 53 and may be deeply 
modulated by sex 34, 35, insulin resistance 38, 39, proinflammatory cytokines 30 and other metabolic 234 
conditions or pathologies 54, 55. The physiologically functional (circulating) protein appears as a dimer 19, 
but the conditions used for Western blot do separate the individual monomers. The main consequence is 236 
the loss, under laboratory conditions, of possible fine regulation factors such as allosteric modulation 56 
and the discrimination of dimers and heterodimers 29. However, the conditions used to determine the 238 
binding value (i.e. specific binding calculated after discounting unspecific binding) facilitate the direct 
comparison of the functionality of the SHBG binding site (there is only one per glycoprotein monomer). 240 
That is, under the testing conditions, the affinity and capacity to bind a given hormone (testosterone or 
estradiol) should remain unchanged. However, the binding / Western blot ratios, experimentally obtained, 242 
clearly were not. This result proves that in one of the groups of individuals (e.g. all the morbidly obese 
men), the SHBG molecule was structurally different. 244 
The existence of varying molecular weight SHBG proteins 28, and the influence of the size of the 
monomers on binding has been already described 53. The changes in the SHBG molecule have been 246 
related to trimming of carbohydrate chains 23 and / or proteolytic shortening, in part attributed to regulatory 
serpin proteases such as kallikrein 26. But changes were observed also in subjects with MS 31, 32, 57, 58, 248 
hepatic cirrhosis 54 or just population variability 31, 32. However, the marked change in SHBG ability to bind 
estradiol in the group of morbidly obese men here described is outstanding. 250 
The binding/ Western ratio for testosterone, was similar in all groups, as expected, including the 
morbidly obese men who also had the lowest levels of immunoreactive SHBG. The hormones' binding 252 
ratios did not show the expected uniform pattern, strongly deviated in morbid obesity instead; however 
this deep change affected only men. Last, but not least, the relationship between the binding capacity of 254 
SHBG and the circulating hormone levels showed large differences for testosterone and estradiol (Figure 
2), in addition to the marked difference due to sex, largely a correlate of the higher circulating 256 
testosterone levels of men. In any case, the percentage of hormone levels vs. binding in control women 
was in the range of 1.5 % whereas that of testosterone was fivefold higher. These values were not within 258 
the expected range of work for SHBG to exert its transporting function under normal conditions; i.e. when 
the maximal proportion of binding sites bound to estradiol represent only a small fraction of the maximal 260 
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binding capacity of the protein, leaving no room for regulation. Consequently, the data on estradiol-related 
transporting capacity of SHBG did not match the currently accepted model of dual transport of androgen 262 
and estrogen for SHBG. 
The results obtained do not support the assumption that SHBG is a protein indistinctly binding 264 
testosterone and estradiol as part of its physiological function. The data presented for males, even if only 
ascribed to the controls and non-extreme obesity (i.e. excluding the morbidly obese men), could not 266 
justify the transporting and regulatory function of SHBG for estradiol because of the sustained low level of 
binding site occupancy. This non-complying situation is magnified when compared with the SHBG-268 
testosterone relationships, since all and every one of the anomalies described for estradiol were fulfilled 
as expected. The phylogenetic closeness of SHBG to the testicular testosterone-binding protein 10, and 270 
the data presented here suggest that SHBG acts, essentially, as a testosterone-binding globulin. The fact 
that SHBG also binds estradiol must be put in perspective 59, especially given the marked differences in 272 
low circulating levels of estradiol compared with testosterone. Competence for a single binding site per 
monomer could not justify a functional role of the protein for estradiol, at least in males: Their much higher 274 
levels of testosterone than women compounded by the higher affinity of SHBG for the androgen, may 
result in negligible estrogen binding as regulatory mechanism in vivo (at least in males and non-ovulating 276 
women). The critical role of estradiol for bone 60, energy homeostasis 61 and reproductive system in both 
females and males 62 has been clearly established, requiring a finer regulation of estrogen in males, 278 
playing functions not fully coincident with those of females. The kinetics of binding of testosterone and 
estradiol did not match their expected function (which nevertheless is exerted successfully), especially 280 
when we consider that SHBG is also a carrier for hormones that bind to specific membrane sites to 
transfer their charge 63. In addition, most studies on SHBG function were centered on testosterone 64, 65. 282 
As a comparison, CBG is devoted to the control of cortisol (or corticosterone in rodents), but also binds 
progesterone and a number of other ligands 66; nnevertheless, no role of CBG in transport or control of 284 
progesterone has been definitively proven. There is thus a clear parallelism between both serpins.  
The apparent increase of estradiol-binding "capacity" in morbidly obese men should be explained 286 
in terms of increased SHBG protein levels, but they were not. Furthermore, testosterone levels were 
unaffected, and the ratios for testosterone binding / Western blot were uniform for all men (and women) 288 
groups, a situation completely different to that of estradiol. A possible explanation of this inconsistency 
must lie on the existence of more than one type of SHBG protein, with at least one specifically binding 290 
estradiol, and the other to testosterone. Thus justifying the data observed in this study, despite 
testosterone alone responding as expected. This interpretation is coincident with previous reports that 292 
found different molecular species of SHBG binding either androgen or estradiol, but not both (in cirrhotic 
patients) 54, as well as the importance and common occurrence of SHBG alleles 22. 294 
The extreme change in estradiol binding of morbidly obese men in comparison with the other 
groups could not be explained by the measured (Western) SHBG protein. But testosterone complies 296 
under the same conditions. Since estradiol levels were much lower, a plausible Estradiol-Binding Globulin 
should be present in the morbidly obese men plasma in lower levels than the "current" or "testosterone-298 
prone" SHBG. This situation mimics that described for cirrhosis 54. The "estradiol-prone" SHBG, 
structurally close to "testosterone-prone" SHBG should be formed by differential post-translational 300 
selective cleavage 26 of the SHBG transcript 22, thus preserving the similarity and similar (albeit probably 
not identical) immunoreactive properties 24 of both SHBG molecular species. The protein measured in this 302 
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study had immunoreactive properties obviously dependent of the affinity and specificity of the antibody 
used, decanted towards one or other of the isoforms postulated, a situation parallel to that described by 304 
our group in rat CBG 52. Thus, in fact, we were not measuring SHBG (under the one molecule-for-all-
hormones concept) but either a composite (with unknown proportions of both isoforms) or essentially one 306 
of these isoforms, that closer to bind / regulate testosterone. Anyway, a change in proportions of both 
forms of SHBG or changes in molar specific immunoreactivity may uncover the existence of more than 308 
one molecular species of circulating SHBG 54. The speculative ascription of different molecular species to 
the roles of transport and binding of estradiol and testosterone may help in understanding the complex 310 
conundrum of SHBG in relation with the control of sex hormone transport, function and their relationships 
under conditions of pathological alterations of energy homoeostasis (30). Sex and age intensify the 312 
negative effects of MS, as observed in Koreans 67. Insulin is known to modulate the levels of testosterone 
through SHBG 30, 68, 69, but what about estradiol? Binding of estradiol or testosterone to SHBG monomers 314 
(and probably dimers) changes their shape 53, thus affecting the conditions of binding to the cell 
membrane SHBG recept r sites. 316 
An additional clue to the importance of the antagonistic gender-related function of cortisol and 
testosterone 37 can be directly derived from the analysis of their concentration ratios, markedly decreased 318 
with obesity in women and less affected in men. These differences are difficult to explain with the 
assumption of a unique SHBG regulating both testosterone and estradiol, since the cortisol / estradiol 320 
concentration ratios were affected by obesity but not by sex. A similar picture can be drawn from the 
ratios of both sex hormones versus insulin: no effects were observed for estradiol, but men (albeit not 322 
women) showed marked effects of obesity, depending on its severity. These data hint at a much more 
significant (and gender-related) implication of testosterone in obesity 70. This is in agreement with the sex-324 
related incidence of the development of MS with age 71, but also with the known relationship of SHBG 
(probably the isoform controlling testosterone availability) and the incidence of MS 58, 72 and the 326 
development of gender-related 73 increased cardiovascular risk. These effects may be largely 
independent of the protective anti-inflammatory effect of estrogen 74. The lack of clear discrimination of 328 
SHBGs and their separate control of estrogen and androgen, has obscured the implication of 
testosterone (or the lack of it) in contrast with the surge of glucocorticoids in the development of 330 
cardiovascular risk in women and old men 75 in parallel to increased frailty 76. Since the fall in testosterone 
levels, at least in men, tend to be related to age 69, and this occurs in parallel to a fall in SHBG levels 65, 332 
we can assume that the results obtained in the present study should be extended to a larger population, 
with a wide age range. The important amount of data available on the dynamics of testosterone action 334 
and protein deposition 77_ENREF_37 in conjunction with the main anabolic hormone, insulin, countered 
by corticosteroids 37 show that testosterone is a critical factor in the aging process 78. The discriminating 336 
role of the postulated dual SHBGs may help understand better the gender-related process of aging by 
establishing a clear mechanism of regulation of the plasma kinetics and transport of testosterone, but will 338 
also allow a deeper study of estrogens without interference. 
In conclusion, our data point to SHBG as a globulin mainly centered in the control of testosterone 340 
levels, with estradiol regulation taking a markedly second place; or, simply, estradiol being controlled by a 
different SHBG variant. These data confirm the existence of different SHBG molecular species to 342 
discriminately bind estradiol and testosterone, previously reported in cirrhotic subjects 54. The sex-related 
differences in the relationships of binding versus levels of hormones and SHBG could not be explained by 344 
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assuming that a single dimeric protein may experience the dramatic changes in affinity for testosterone 
and estradiol (differently for both, in fact) observed in women and men, and the marked differential effects 346 
of obesity on the ability of the same protein to bind testosterone and estradiol (Box 1).  
Thus, we postulate that SHBG protein must be present in at least two different molecular species, 348 
or isoforms, to explain its differential function for both hormones, specially affected by sex and obesity. 
These conclusions suggest a much needed establishment of analytical procedures to identify these 350 
physiologically distinct forms of SHBG, since the sole use of antibody-based measurements could not 
discriminate between them. 352 
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FIGURE LEGENDS 600 
 
Figure 1 Estradiol and testosterone binding, as well as their ratio, for women and men of normal 602 
weight, obese and morbidly obese 
The data are the mean ± sem for each group. White: women, grey: men; WC = women of normal weight; 604 
WO = women obese; WMO = women morbidly obese; MC = men of normal weight; MO = men obese; 
MMO = men morbidly obese. Statistical analysis of the differences between groups: Two-way ANOVA, 606 
(data within the Figure) was carried out for the parameters "sex" (S) and "obesity" (O). NS represents P 
values higher than 0.050. One-way ANOVA for obesity in each sex group (data on top of the Figure) O-W 608 
factor "obesity" in women; O-M factor "obesity" in men. Post-hoc Duncan test for one-way ANOVAs 
(obesity): different letters over the columns indicate a significant (P<0.05) difference between them; the 610 
absence of letters reflects the absence of significant differences between the groups. 
 612 
Figure 2 Relationship between the levels of estradiol or testosterone in plasma with respect to the 
binding ability of this same plasma, expressed as percentages. 614 
Figure conventions are the same as in Figure 1. 
 616 
Figure 3 SHBG Western blot of women and men of normal weight, obese and morbidly obese 
Figure conventions are the same as in Figure 1; a.u. = arbitrary units (the MC mean value was attributed 618 
the arbitrary value of 100). 
 620 
Figure 4 Ratios of estradiol and testosterone binding versus the SHBG Western blot data, for 
women and men of normal weight, obese and morbidly obese 622 
Figure conventions are the same as in Figure 1. 
 624 
Box 1  The SHBG dual hormone-binding conundrum 
Summary of the available reasons and experimental data proving the unsustainability of the SHBG dual 626 
role controlling / transporting estradiol and testosterone 
T = testosterone, E2 = estradiol 628 
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Table 1 Basic characteristics of the human subject groups used in the present study 
 
parameters units 
women men P 
normal weight obese morbid obese normal weight obese morbid obese sex obesity interaction 
number of individuals  14 10 8 13 9 8 -- -- -- 
age years 36 ± 2 32 ± 2 32 ± 1 35 ± 2 41 ± 3 36 ± 2 NS NS NS 
weight kg 61 ± 1 90 ± 3 121 ± 5 69 ± 2 101 ± 4 141 ± 10 0.0003 <0.0001 NS 
height m 1.66 ± 0.01 1.64 ± 0.02 1.64 ± 0.02 1.74 ± 0.02 1.75 ± 0.03 1.76 ± 0.03 <0.0001 NS NS 
BMI kg/m
2
 22.2 ± 0.4 33.4 ± 1.0 45.0 ± 1.3 22.7 ± 0.3 33.2 ± 0.8 45.4 ± 2.2 NS <0.0001 NS 
fasting plasma glucose mM 4.73 ± 0.13 4.76 ± 0.12 4.97 ± 0.15 5.32 ± 0.15 5.52 ± 0.16 6.13 ± 0.21 <0.0001 0.0040 NS 
HbA1C % 4.6 ± 0.1 4.9 ± 0.1 4.8 ± 0.2 4.8 ± 0.1 4.7 ± 0.1 5.4 ± 0.2 NS 0.0030 0.0270 
HOMA-IR  1.25 ± 0.18 2.43 ± 0.36 2.44 ± 0.33 1.40 ± 0.23 3.19 ± 0.64 3.96 ± 0.42 0.0094 <0.0001 NS 
total plasma cholesterol mM 4.53 ± 0.13 5.00 ± 0.29 5.23 ± 0.27 5.23 ± 0.21 5.72 ± 0.19 5.39 ± 0.41 0.0128 NS NS 
HDL-cholesterol mM 1.51 ± 0.11 1.30 ± 0.08 1.31 ± 0.11 1.32 ± 0.11 1.27 ± 0.11 1.04 ± 0.08 NS NS NS 
LDL-cholesterol mM 2.69  0.17 3.09 ± 0.24 3.18 ± 0.29 3.45 ± 0.21 3.74 ± 0.17 3.39 ± 0.42 0.0107 NS NS 
plasma triacylglycerols mM 0.779 ± 0.054 1.37 ± 0.30 1.66 ± 0.19 1.13 ± 0.18 1.67 ± 0.33 2.14 ± 0.26 0.0422 0.0002 NS 
 
The values are presented as mean ± sem for each group. Statistical analysis of the differences between groups (2-way ANOVA) was carried out for the 
parameters "sex", "obesity" and their interaction. NS represents P values higher than 0.050. 
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Table 2 Hormone levels in serum of women and men with normal weight, obese or morbidly obese. 
 
plasma hormones 
and hormone ratios 
units sex normal weight obese morbid obese 1-way anova 2-way anova 
P-obesity P-sex P-obesity P-interaction 
estradiol pM women 162 ± 29 173 ± 25 256 ± 48 NS NS 0.0043 NS 
men 134 ± 16 
A
 124 ± 13 
A
 215 ± 22 
B
 0.0044 
testosterone nM women 1.19 ± 0.18 
A
 1.59 ± 0.23 
AB
 2.31 ± 0.36 
B
 0.0125 <0.0001 0.0040 0.0002 
men 19.6 ± 1.4 
A
 17.4 ± 1.8 
A
 11.1 ± 1.1 
B
 0.0020 
cortisol nM women 407 ± 38 374 ± 64 277 ± 64 NS NS NS NS 
men 354 ± 27 382 ± 34 333 ± 74 NS 
insulin pM women 42.2 ± 5.4 
A
 82.5 ± 12.1 
B
 77.4 ± 10.9 
B
 0.0034 NS <0.0001 NS 
men 41.4 ± 6.2 
A
 93.1 ± 17.7 
B
 103 ± 10 
B
 0.0004 
testosterone/ 
estradiol ratio 
 women 6.73 ± 1.10 
A
 8.19 ± 0.80 
AB
 10.3 ± 1.4 
B
 NS <0.0001 0.0078 0.0046 
men 176 ± 27 
A
 155 ± 19 
A
 57.9 ± 11.5 
B
 0.0084 
cortisol/ testosterone 
ratio 
 women 441 ± 65 
A
 277 ± 59 
AB
 136 ± 37 
B
 0.0074 <0.0001 0.0063 0.0045 
men 19.1 ± 2.1 23.0 ± 2.3 24.2 ± 5.4 NS 
cortisol/ estradiol 
ratio 
x10
-3
 women 3.23 ± 0.67 2.27 ± 0.53 1.49 ± 0.61 NS NS 0.0087 NS 
men 3.16 ± 0.47 
A
 3.25 ± 0.40 
A
 1.47 ± 0.33 
B
 0.0280 
estradiol/ insulin 
ratio 
 women 3.66 ± 0.68 4.43 ± 1.50 3.82 ± 0.88 NS NS NS NS 
men 4.49 ± 0.98 
A 
1.54 ± 0.20 
B 
2.26 ± 0.39 
AB 
NS 
testosterone/ insulin 
ratio 
 women 31.5 ± 7.2 33.6 ± 12.6 33.6 ± 6.2 NS <0.0001 0.0006 0.0005 
men 681 ± 142 
A
 232 ± 32 
B
 112 ± 13 
B
 0.0020 
 
The values are presented as mean ± sem for each group. Statistical analysis of the differences between groups (1- and 2-way ANOVA) was carried out for the 
parameters "sex", "obesity" and their interaction. NS represents P values higher than 0.050. Post-hoc Duncan test for 1-way anovas: different superscript 
letters represent significant differences between the corresponding groups 
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Figure 1  
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Figure 2 Relationship between the levels of estradiol or testosterone in plasma with respect to the binding 
ability of this same plasma, expressed as percentages.  
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Figure 3 SHBG Western blot of women and men of normal weight, obese and morbidly obese  
Figure 3  
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Figure 4 Ratios of estradiol and testosterone binding versus the SHBG Western blot data, for women and 
men of normal weight, obese and morbidly obese  
Figure 4  
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The SHBG dual hormone binding conundrum 
Current accepted knowledge: 
 A unique SHBG binds, transports and regulates the levels and availability of T and E2 
Already known data that so not support the "single SHBG" current theory 
• M and W show different (and varying) levels of T and E2 with similar SHBG 
protein concentrations 
• Widely different T and E2 levels in plasma apparently do not compete or interfere 
on SHBG function despite using a single binding site for which they compete as 
ligands 
• Different SHBG forms have been found in humans with structural and binding 
affinity differences for T and E2) 
• Many animals do not have SHBG, but most possess non-circulating T-binding 
proteins; i.e. T may be regulated independently of E2. In any case T and E2 
levels are regulated in plasma despite the eventual absence of SHBG 
Additional proof, presented here, against the "single SHBG" current theory 
• Circulating E2 (lower than T) at most may cover 3% of the potential binding sites 
of concurrent plasma SHBG, which is not compatible with T occupying 65-90 % 
of the sites. These data anr not compatible with a regulation role of SHBG for E2 
• Obesity affects T (but not E2) binding. This is incompatible with both hormones 
binding (competing) for the same SHBG binding site if the protein remains 
unchanged 
• The ratio of hormone binding vs. protein level (Western blot) should be constant 
unless the protein affinity is changed (by changing the protein itself). The ratio for 
T is unaltered by sex and obesity, but that for E2 is affected by both 
The conclusions are far reaching: 
• Cannot be explained by the single type of SHBG, which brings us to assume 
that, at least there are two SHBGs, one regulating T and the other for E2 
• Most of the methods used for the measurement of SHBG rely on their 
immunoreactivity, but they may detect/ measure a T- or E2-prone SHBG 
molecular species of a mixture of both in different proportions 
• Consequently, there are no reliable methods for SHBG measurement available, 
in the sense that SHBG levels could not be related to a specific protein carrying 
out a specific function. This, largely invalidates many studies on SHBG function 
• Specific discriminative methods for the SHBGs may help clarify the intuited role 
of estrogens and androgens on metabolic syndrome-related pathologic states. 
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